

PRESS RELEASE

Gradientech receives US patent allowance for its QuickMIC® test

Uppsala, Sweden, April 23, 2026. **Gradientech today announces having received a Notice of Allowance in the United States for its single-use microfluidic test, a key component of the CE marked QuickMIC® system – the fastest diagnostic solution on the market for antibiotic susceptibility testing (AST) directly from blood cultures, enabling improved sepsis patient management.**

The U.S. Patent and Trademark Office has recognised the originality of the construction of the QuickMIC® test device design as part of the IVDR certified QuickMIC® solution by Gradientech. The U.S. patent application, based on International Publication Number WO 2020/204799, covers the design and functionality of the test device assembly, including microfluidic components, critical optical elements that hold and monitor patient microorganisms during testing, and the device's encapsulation features.

Once granted, the U.S. patent will be valid until at least 2040. Patents within the same family are already registered in selected European countries, Japan and China.

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.